Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14964736 | 0.98 | KDM4E (0.38) | KDM4EKMT2AOPRM1NPSR1CYP1A2 | |
| SCHEMBL12373913 | 0.88 | NPSR1 (0.34) | KDM4EKMT2AOPRM1NPSR1LMNA | |
| SCHEMBL2270690 | 0.88 | NPSR1 (0.34) | KDM4EKMT2AOPRM1NPSR1LMNA | |
| SCHEMBL1469083 | 0.84 | — | — | |
| SCHEMBL21963901 | 0.80 | OPRM1 (0.43) | KDM4EKMT2AOPRM1NPSR1CYP4F2 | |
| SCHEMBL27914276 | 0.80 | KDM4E (0.35) | KDM4EKMT2AOPRM1NPSR1SIGMAR1 | |
| SCHEMBL23182251 | 0.80 | KDM4E (0.36) | KDM4EKMT2AOPRM1CYP1A2SIGMAR1 | |
| SCHEMBL11888828 | 0.80 | KDM4E (0.36) | KDM4EKMT2AOPRM1CYP1A2SIGMAR1 | |
| SCHEMBL25228494 | 0.79 | NPSR1 (0.45) | KMT2ANPSR1CYP1A2LMNACYP4F2 | |
| SCHEMBL2775123 | 0.79 | NPSR1 (0.50) | KMT2ANPSR1CYP1A2LMNACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2897948-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2015-07-29 | — | — | EP | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2780015-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | KDM4E 3975/4885KMT2A 2583/4885OPRM1 31/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | KDM4E 2177/4885KMT2A 2722/4885OPRM1 4203/4885 |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | KDM4E 3975/4885KMT2A 2583/4885OPRM1 31/4885 |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM5 | KDM4E 907/4885KMT2A 887/4885OPRM1 61/4885 |
| US-10973832-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | KDM4E 3975/4885KMT2A 2583/4885OPRM1 31/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | KDM4E 1312/4885KMT2A 1686/4885OPRM1 3889/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | KDM4E 4724/4885KMT2A 3866/4885OPRM1 144/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | KDM4E 3975/4885KMT2A 2583/4885OPRM1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.